Anastasia MacDonald, Moustafa Fathy, Parsa Nikoufar, A. Hodhod, Ruba Abdul Hadi, Saud Alhelal, Husain Alaradi, A. Zakaria, W. Shahrour, H. Elmansy
{"title":"Efficacy of GreenLight laser prostatectomy in urinary retention","authors":"Anastasia MacDonald, Moustafa Fathy, Parsa Nikoufar, A. Hodhod, Ruba Abdul Hadi, Saud Alhelal, Husain Alaradi, A. Zakaria, W. Shahrour, H. Elmansy","doi":"10.5489/cuaj.8556","DOIUrl":null,"url":null,"abstract":"Introduction: The objective of our study was to evaluate the efficacy and durability of GreenLight laser prostatectomy for the management of acute urinary retention (AUR) and chronic urinary retention (CUR) and to determine outcomes compared to patients without preoperative urinary retention (UR).\nMethods: We conducted a retrospective study of prospectively collected data from individuals who underwent GreenLight laser prostatectomy at our institution from May 2018 to July 2022. Patient demographics and outcome measures were recorded, including indications for the procedure, median urinary volume drained, or median postvoid residual urine volume (PVR) before catheterization or GreenLight laser prostatectomy. CUR was defined as PVR >300 mL in males able to void and initial catheter drainage >1000 mL in males unable to void in the absence of pain. All patients had postoperative followup visits at one, three, six, and 12 months. Our evaluation included the International Prostate Symptom Score (IPSS), quality-of-life (QoL) assessment, maximum urinary flow rate (Qmax), PVR, and catheter-free status.\nResults: One hundred sixty-eight males who underwent GreenLight laser prostatectomy were included in our study. The UR group consisted of 88 patients (50 AUR and 38 CUR), and the lower urinary tract symptoms (LUTS) group was comprised of 80 individuals. There were no statistically significant differences between the AUR and CUR subgroups regarding demographics. The UR group had a significantly higher age and a significantly higher postoperative catheterization length (p=0.000 and 0.000, respectively) compared to the LUTS cohort. The CUR subgroup had a significantly higher PVR at one, three, and six months compared to the AUR subgroup, although other outcome measures were similar between the two cohorts. During three- and 6-month followup visits, the UR group had a significantly higher PVR than the LUTS cohort. At 12 months postoperative, the LUTS group had a higher catheter-free rate than the UR group (p=0.001). The successful first trial of void (TOV) rate for the UR and LUTS groups were 83% and 80%, respectively. At 12 months followup, the catheter-free rate for the UR and LUTS cohorts was 87.5% and 100%, respectively.\nConclusions: GreenLight laser prostatectomy is an effective and durable treatment for UR with a high catheter-free rate and comparable outcomes when performed to manage LUTS.","PeriodicalId":38001,"journal":{"name":"Canadian Urological Association Journal","volume":"37 19","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Urological Association Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5489/cuaj.8556","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The objective of our study was to evaluate the efficacy and durability of GreenLight laser prostatectomy for the management of acute urinary retention (AUR) and chronic urinary retention (CUR) and to determine outcomes compared to patients without preoperative urinary retention (UR).
Methods: We conducted a retrospective study of prospectively collected data from individuals who underwent GreenLight laser prostatectomy at our institution from May 2018 to July 2022. Patient demographics and outcome measures were recorded, including indications for the procedure, median urinary volume drained, or median postvoid residual urine volume (PVR) before catheterization or GreenLight laser prostatectomy. CUR was defined as PVR >300 mL in males able to void and initial catheter drainage >1000 mL in males unable to void in the absence of pain. All patients had postoperative followup visits at one, three, six, and 12 months. Our evaluation included the International Prostate Symptom Score (IPSS), quality-of-life (QoL) assessment, maximum urinary flow rate (Qmax), PVR, and catheter-free status.
Results: One hundred sixty-eight males who underwent GreenLight laser prostatectomy were included in our study. The UR group consisted of 88 patients (50 AUR and 38 CUR), and the lower urinary tract symptoms (LUTS) group was comprised of 80 individuals. There were no statistically significant differences between the AUR and CUR subgroups regarding demographics. The UR group had a significantly higher age and a significantly higher postoperative catheterization length (p=0.000 and 0.000, respectively) compared to the LUTS cohort. The CUR subgroup had a significantly higher PVR at one, three, and six months compared to the AUR subgroup, although other outcome measures were similar between the two cohorts. During three- and 6-month followup visits, the UR group had a significantly higher PVR than the LUTS cohort. At 12 months postoperative, the LUTS group had a higher catheter-free rate than the UR group (p=0.001). The successful first trial of void (TOV) rate for the UR and LUTS groups were 83% and 80%, respectively. At 12 months followup, the catheter-free rate for the UR and LUTS cohorts was 87.5% and 100%, respectively.
Conclusions: GreenLight laser prostatectomy is an effective and durable treatment for UR with a high catheter-free rate and comparable outcomes when performed to manage LUTS.
期刊介绍:
Published by the Canadian Urological Association, the Canadian Urological Association Journal (CUAJ) released its first issue in March 2007, and was published four times that year under the guidance of founding editor (Editor Emeritus as of 2012), Dr. Laurence H. Klotz. In 2008, CUAJ became a bimonthly publication. As of 2013, articles have been published monthly, alternating between print and online-only versions (print issues are available in February, April, June, August, October, and December; online-only issues are produced in January, March, May, July, September, and November). In 2017, the journal launched an ahead-of-print publishing strategy, in which accepted manuscripts are published electronically on our website and cited on PubMed ahead of their official issue-based publication date. By significantly shortening the time to article availability, we offer our readers more flexibility in the way they engage with our content: as a continuous stream, or in a monthly “package,” or both. CUAJ covers a broad range of urological topics — oncology, pediatrics, transplantation, endourology, female urology, infertility, and more. We take pride in showcasing the work of some of Canada’s top investigators and providing our readers with the latest relevant evidence-based research, and on being the primary repository for major guidelines and other important practice recommendations. Our long-term vision is to become an essential destination for urology-based research, education, and advocacy for both physicians and patients, and to act as a springboard for discussions within the urologic community.